Literature DB >> 2161800

CpG methylation of viral DNA in EBV-associated tumours.

M J Allday1, D Kundu, S Finerty, B E Griffin.   

Abstract

In EBV-immortalized lymphoblastoid cell lines (LCLs) a small number of "latent" proteins are expressed. These are the EBV nuclear antigens, EBNAs 1-6, and a latent membrane protein, LMP. We have investigated the expression of these proteins in a variety of EBV-associated tumours and cell lines. Whereas transplant and B-cell lymphomas from cotton-top tamarins appear to express the full range of antigens found in LCLs, we and others have found that in Burkitt's lymphomas (BL) and a nasopharyngeal carcinoma (NPC) isolate, EBNA expression is restricted to EBNA-I. (In NPC, but not in BL, LMP may also be expressed). In order to ask what restricts the expression of EBNA 2-6 in NPC and BL cells it seemed reasonable to consider the possibility that the DNA sequences normally regulating expression of these antigens could be chemically modified. In this analysis, a tight inverse correlation between methylation of CpG dinucleotides in the 5' flanking region of the EBNA-2 gene and the expression of EBNAs 2-6 has been revealed. In the NPC tumour, CpG methylation within the gene is also observed, as is specific methylation over the EBNA-I region I and II binding sites (in oriP). The significance of these observations is considered.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161800     DOI: 10.1002/ijc.2910450623

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Methylation status of the Epstein-Barr virus (EBV) BamHI W latent cycle promoter and promoter activity: analysis with novel EBV-positive Burkitt and lymphoblastoid cell lines.

Authors:  Isabel A Hutchings; Rosemary J Tierney; Gemma L Kelly; Julianna Stylianou; Alan B Rickinson; Andrew I Bell
Journal:  J Virol       Date:  2006-08-18       Impact factor: 5.103

2.  Expression of cyclin D2 in Epstein-Barr virus-positive Burkitt's lymphoma cell lines is related to methylation status of the gene.

Authors:  A J Sinclair; I Palmero; A Holder; G Peters; P J Farrell
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

3.  Differential expression of Epstein Barr viral transcripts for two proteins (TP1 and LMP) in lymphocyte and epithelial cells.

Authors:  P R Smith; B E Griffin
Journal:  Nucleic Acids Res       Date:  1991-05-11       Impact factor: 16.971

4.  Methylation of transcription factor binding sites in the Epstein-Barr virus latent cycle promoter Wp coincides with promoter down-regulation during virus-induced B-cell transformation.

Authors:  R J Tierney; H E Kirby; J K Nagra; J Desmond; A I Bell; A B Rickinson
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  CTCF prevents the epigenetic drift of EBV latency promoter Qp.

Authors:  Italo Tempera; Andreas Wiedmer; Jayaraju Dheekollu; Paul M Lieberman
Journal:  PLoS Pathog       Date:  2010-08-12       Impact factor: 6.823

6.  Complex nature of the major viral polyadenylated transcripts in Epstein-Barr virus-associated tumors.

Authors:  P R Smith; Y Gao; L Karran; M D Jones; D Snudden; B E Griffin
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

7.  Methylation of discrete sites within the enhancer region regulates the activity of the Epstein-Barr virus BamHI W promoter in Burkitt lymphoma lines.

Authors:  A Jansson; M Masucci; L Rymo
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

Review 8.  Immune regulation in Epstein-Barr virus-associated diseases.

Authors:  R Khanna; S R Burrows; D J Moss
Journal:  Microbiol Rev       Date:  1995-09

9.  Epstein-Barr virus in gastric adenocarcinomas: association with ethnicity and CDKN2A promoter methylation.

Authors:  Q N Vo; J Geradts; M L Gulley; D A Boudreau; J C Bravo; B G Schneider
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

Review 10.  Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology.

Authors:  Martin Rowe; Gemma L Kelly; Andrew I Bell; Alan B Rickinson
Journal:  Semin Cancer Biol       Date:  2009-07-18       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.